Product Information
ERY 2% PADS is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $1.2300 per EA under NDC 45802096272. Its NADAC has been published 378 times since Nov 28, 2013.
FDA first approved this application on Jul 3, 1996. Its Orange Book therapeutic-equivalence code is AT.
Strength
20 mg/mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802096272
Classification
Generic
Dosage Form
SWAB
Route
TOPICAL
Effective Date
8/19/2026
Active Ingredients
ERYTHROMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA064126FDA Approved
7/3/1996
TE Code
AT
On Market Since
7/7/2008
Pharmacological Classes
Price Statistics
The NADAC for ERY 2% PADS has been published 378 times since Nov 28, 2013, and over the history we have for it it has risen 22.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2300 per EA |
|---|---|
| All-time high | $1.2380 (Aug 12, 2026) |
| All-time low | $0.8571 (May 17, 2017) |
| 52-week high | $1.2380 |
| 52-week low | $1.2121 |
| Median price | $1.0068 |
| Average price | $1.0478 |
| Largest weekly change | +28.8% (Apr 17, 2024) |
| Weeks tracked | 378 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Erythromycin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ERY 2% PADS?
The current National Average Drug Acquisition Cost (NADAC) for ERY 2% PADS, manufactured by Padagis Israel Pharmaceuticals Ltd, is $1.2300 per EA (NDC 45802096272), effective Aug 19, 2026.
How has the price of ERY 2% PADS changed over time?
Over the history we have for it, the NADAC for ERY 2% PADS has risen 22.3%. It has been tracked across 378 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ERY 2% PADS?
Since Nov 28, 2013, the NADAC for ERY 2% PADS has ranged from a low of $0.8571 (May 17, 2017) to a high of $1.2380 (Aug 12, 2026), with a median of $1.0068 per EA.
Are there cheaper alternatives to ERY 2% PADS?
No other NADAC-published product currently shares the active ingredient and strength of ERY 2% PADS in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ERY 2% PADS?
ERY 2% PADS (NDC 45802096272) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.